• 3070 Bristol Pike, Suite 112, Bensalem, PA 19020

  • Call Us: (215) 638-4847 |

    Fax: (215) 638-4867

Novo Nordisk A/S (NYSE: NVO)

Case Details

Join The Class Action

This lawsuit is for anyone who acquired securities in Novo Nordisk A/S (NYSE: NVO) from May 7, 2025 through July 28, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by failing to timely inform investors that the Company was ending it partnership with Hims & Hers Health, Inc. because the later was violating the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization.’

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of ‘personalization’ and are disseminating deceptive marketing that put patient safety at risk.” Novo Nordisk further stated “the ‘semaglutide’ active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies” may contain “unsafe and illicit foreign ingredients.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume. Then, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, the price of the Company’s stock again dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Novo Nordisk A/S (NYSE: NVO) from May 7, 2025 through July 28, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.